Hospital staff are at high risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the coronavirus disease (COVID-19) pandemic. This cross-sectional study aimed to determine the prevalence of SARS-CoV-2 infection in hospital staff at the University Hospital rechts der Isar in Munich, Germany, and identify modulating factors. Overall seroprevalence of SARS-CoV-2-IgG in 4,554 participants was 2.4%. Staff engaged in direct patient care, including those working in COVID-19 units, had a similar probability of being seropositive as non–patient-facing staff. Increased probability of infection was observed in staff reporting interactions with SARS-CoV-2–infected co-workers or private contacts or exposure to COVID-19 patients without appropriate personal protective equipment. Analysis of spatiotemporal trajectories identified that distinct hotspots for SARS-CoV-2–positive staff and patients only partially overlap. Patient-facing work in a healthcare facility during the SARS-CoV-2 pandemic might be safe as long as adequate personal protective equipment is used and infection prevention practices are followed inside and outside the hospital.

Healthcare workers (HCWs) are exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the private context, as well as professionally with varying exposure risk depending on their workplace. Prevalence rates have been measured as high as 13.7% in the New York, NY, USA, area, 10.2% in a nationwide study in Spain, 7.5% for 580 HCWs in a hospital in Spain, 6.4% for >3,000 HCWs in a tertiary hospital in Belgium, 4.0% for >2,879 HCWs in Denmark, and 0.4%–3.8% for hospitals in China (1–6). Working in coronavirus disease (COVID-19)–designated units has been reported to carry an increased risk for infection (4,7).

The greater Munich area in Germany became the epicenter of a SARS-CoV-2 outbreak after a confirmed case was reported on January 27, 2020. A rapid and massive increase in SARS-CoV-2 infections occurred during March 2020, when infected persons returned from skiing resorts, such as Ischgl, Austria, where the spread of infection was dramatic (8). The University Hospital Munich rechts der Isar faced the challenge of rapidly increasing numbers of COVID-19 patients, combined with an increasing number of staff in quarantine. To reduce the spread of infections, guidelines for the use of personal protective equipment (PPE) for staff and patients were introduced, including the obligation to wear face masks in all areas of the hospital (Figure 1). In addition, a telephone hotline was established to provide staff with guidance for reverse transcription PCR (RT-PCR) testing and quarantine policies.
To determine the epidemiology and immune response to SARS-CoV-2 and to identify best-practice approaches protecting staff and patients, we initiated a prospective, observational cohort study. The purpose of this study was to assess risk factors and evidence for infection, including clinical symptoms, and to determine the seroprevalence of SARS-CoV-2 antibodies.

Materials and Methods

Study Design and Participants
During April 14–May 29, 2020, all clinical and nonclinical Munich rechts der Isar staff ≥18 years of age (n = 6,305) and medical students at the Technical University of Munich (n = 1,699) were invited to participate in this prospective, monocentric, observational study (Appendix Figure 1, https://wwwnc.cdc.gov/EID/article/27/3/20-4436-App1.pdf). Previous positive SARS-CoV-2 antibody tests results was not an exclusion criterion. Upon receiving written informed consent, we obtained demographic data; chronic medical conditions; occupation; work location; use of PPE; exposure to SARS-CoV-2–positive patients, co-workers, or private contacts; symptom history; previous PCR testing for SARS-CoV-2; and outcome by using a standardized electronic questionnaire (Appendix) before the blood test result was known. We defined endoscopy, bronchoscopy, tracheal intubation, noninvasive ventilation, and transesophageal echocardiography as aerosol-generating medical procedures (AGPs).

We collected serum samples and subjected them to SARS-CoV-2 IgG and IgM testing (primary outcome). We tested for IgM in all persons until May 4, 2020 (n = 1,620), and thereafter only if IgG was positive or typical symptoms of COVID-19 were reported (n = 88) (Appendix Figure 2). Staff reporting symptoms or testing positive for IgM were recommended to undergo testing of nasopharyngeal swab specimens for SARS-CoV-2 by RT-PCR to exclude persistent infection. We stored personal data in a pseudonymized manner by using the open-source electronic case form system m4 DIS (BitCare GmbH, https://www.bitcare.de) (9). The study was approved by the Ethics Committee of the Technical University of Munich School of Medicine (approval no. 216/20S).

Since March 2020, a continuous infection surveillance program for all staff has been implemented at the University Hospital rechts der Isar in Munich, including an employee testing center and staff counseling (Corona Hotline), which is available 7 days per week. Persons who have symptoms compatible with COVID-19 or previous risk contacts are scheduled for testing for SARS-CoV-2 by RT-PCR from combined oropharyngeal and nasopharyngeal swab specimens.
We included RT-PCR results of staff testing in the analysis if the study participants consented.

**Laboratory Analysis**

We detected serum IgM and IgG against SARS-CoV-2 spike 1 protein or nucleocapsid protein by using a paramagnetic particle chemiluminescent immunoassay on an iFlash 1800 Immunoassay Analyzer (Shenzhen Yhlo Biotech Co., http://en.szyhlo.com). We subjected all serum samples that were positive for IgM or IgG (≥10 AU/mL), all serum samples that had 5–10 AU/mL of IgG, and all serum samples from SARS-CoV-2 RT-PCR–positive persons to confirmatory testing. For confirmation, we determined total antibodies against SARS-CoV-2 nucleocapsid by using an electrochemiluminescent immunoassay on a Cobas e411 Analyzer (Roche Diagnostics, https://www.roche.com). For all samples that had incongruent results, we determined IgG against SARS-CoV-2 spike 1 protein by using an ELISA (Euroimmun, https://www.euroimmun.com) and used immunoblotting to differentiate antibodies against nucleocapsid protein, spike 1 protein 1, and the receptor-binding domain of SARS-CoV-2 from those against seasonal coronaviruses (Mikrogen, https://www.mikrogen.de) (Appendix).

We extracted nucleic acids from nasopharyngeal swab specimens by using the mSample Preparation System DNA Kit identical to the Promega Maxwell Viral Total Nucleic Acid Extraction Kit (Promega, https://www.promega.com) according to a standard protocol on an m2000sp Device for RNA and DNA Extraction (Abbott, https://www.abbott.com). SARS-CoV-2 RT-PCR was performed by using SARS-CoV-2_N1 and SARS-CoV-2_N2 primer and probe sets for amplification on an ABI 7500 Device (ThermoScientific, https://www.thermoscientific.com) according to the protocol of the Centers for Disease Control and Prevention (Atlanta, GA, USA), as approved by the US Food and Drug Administration.

**Analysis of Patient and Staff Trajectories**

We extracted anonymized patient mobility trajectory data from our hospital information system. COVID-19 was diagnosed when patients either showed typical clinical symptoms or had COVID-19–typical findings in low-dose lung computed tomography scans and tested positive for SARS-CoV-2 by RT-PCR or for SARS-CoV-2 IgM or IgG (10). For spatiotemporal analysis of patient data, we used all trajectories available during December 30, 2019–May 29, 2020, for each admitted COVID-19 patient because we could not determine the exact interval when the patients were contagious. We obtained trajectories of SARS-CoV-2 IgG seropositive staff from our questionnaire data if available (February 1–May 29, 2020).

On the basis of the spatiotemporal trajectories of patients and staff, we created 2 types of representations: static representations over all timeframes and dynamically animated representations. The static representation is based on the relative proportion of patients or staff members at each hospital location normalized by all locations of the available trajectory time. For the dynamic representation, we illustrated 2 different relative proportions normalized by all timeframes: the relative proportion of individual patients in each hospital location and the relative proportion of staff members mapped to their past locations for 14 days before they tested positive for SARS-CoV-2 IgG or were quarantined.

To analyze patient mobility within the hospital during the pandemic, we compared the spatial trajectories of COVID-19 patients to all patients given a diagnosis of any non–COVID-19 pneumonia (viral or bacterial) during December 1, 2019–June 10, 2020 (Appendix Figure 3). We performed all analyses by using R software version 3.6.0 (R Foundation for Statistical Computing, https://www.r-project.org) and made the source code available on GitHub (https://github.com/AnaGalhoz37/SeCOMRI).

**Statistical Analysis**

Absolute and relative frequencies of positive test results for SARS-CoV-2 IgG and IgM (Chemiluminescence Immunoassay, Shenzhen Yhlo Biotech Co.) are given for all study participants and relevant subgroups, along with exact 95% CIs for the estimated seroprevalence. To evaluate the association with potential risk factors, we estimated odds ratios (ORs) and corresponding exact 95% CIs (mid-p intervals). The distributions of antibody titers are visualized by boxplots or dot plots and are described by medians and quartiles. We used the Spearman rank correlation coefficient to evaluate the association between the time of IgG testing and the IgG titer. We did not adjust the 95% CI widths for multiplicity. Missing data were not imputed, and the number of missing values is presented for each variable. We conducted statistical analyses by using R software version 4.0.2 (R Foundation for Statistical Computing).

**Results**

**Seroprevalence of SARS-CoV-2 IgG for 4,554 Hospital Employees**

The study participation rate was 63.5% (4,001/6,305) for employees and 35.5% (603/1,699) for medical
students; complete data for 4,554 persons were available for primary analysis (Appendix Figure 1). The mean age of the study participants was 38.5 years; 3,207 (70.4%) were women and 1,342 (29.5%) were men (Appendix Figure 4). Positive results for SARS-CoV-2 IgG were found for 108/4,554 study participants. For 102 persons, additional assays confirmed the SARS-CoV-2 IgG screening result (Appendix Table 1). Two additional persons who had a positive PCR result seroconverted during follow-up. Four persons who had IgG titers of 5–10 AU/mL in the screening assay, which is below the cutoff, were found to be positive in ≥2 other assays (Appendix Tables 1, 2). For 5 persons, the screening result could not be confirmed by the other assays used; for 1 person, there was insufficient material available to complete testing (Appendix Tables 3, 4). When we considered all 108 study participants who were positive for SARS-CoV-2 IgG in ≥2 different assays, we determined a seroprevalence of 2.4% (95% CI 1.9%–2.9%) (primary endpoint).

### Individual and Occupational Risk Factors for SARS-CoV-2 Infection

The first patient who had PCR-confirmed COVID-19 was admitted to our university hospital on March 6, 2020, and 163 COVID-19 patients were hospitalized during March 6–May 29 (Figure 1). Infection prevention measures, such as the obligation to wear surgical masks, physical distancing measures, visitor rules, or policies for nonurgent procedures, were dynamically adjusted according to the prevalent pandemic situation (Table 2; Figure 2, panel A; Appendix Figure 5). We found a higher relative frequency of seropositivity for persons who had diabetes mellitus (OR 2.96, 95% CI 1.01–6.81) but observed no major differences in staff who had preexisting pulmonary or cardiovascular disease (Table 2; Appendix Figure 5). Seropositivity was decreased for smokers (OR 0.52, 95% CI 0.26–0.94) (Table 2); relevant difference in seropositivity was observed between HCWs involved in direct patient care, including care of COVID-19 patients, and HCWs working in intensive care units or the emergency department compared with staff members not working in these units and not performing patient-associated tasks (Table 2; Figure 2, panel A; Appendix Figure 5).

Conversely, we found that seropositivity was particularly high for administrative staff who did not have any direct patient contact (OR 2.36, 95% CI 1.19–4.80) (Table 1; Figure 2, panel B; Appendix Figure 5). Nonclinical staff were not obliged to wear masks at work at the beginning of the pandemic (Figure 1). Seropositivity was also markedly increased in staff who reported exposure to co-workers (OR 1.74, 95% CI 1.11–2.65) or private contacts with persons who had SARS-CoV-2 infections (OR 5.56, 95% CI 3.32–8.94) (Table 2; Figure 2, panel A; Appendix Figure 5). Self-reported unprotected contact with COVID-19 patients (no surgical mask, <1.5-m distance, or AGP without proper protection) was associated with a 5.56-fold increase in relative frequency of seropositivity (OR 5.56, 95% CI 3.32–8.94) (Table 2; Figure 2, panel B; Appendix Figure 5).

### Table 1. Seroprevalence of SARS-CoV-2 infections in patients and staff, by general characteristics and occupation, at a university hospital, Munich, Germany*

| Characteristic | SARS-CoV-2 IgG, no. (%) | Odds ratio (95% CI) |
|---------------|------------------------|---------------------|
| Age group, y  |                        |                     |
| 18–30, n = 1,622 | 1,585 (97.7) | 37 (2.3) | Referent |
| 31–40, n = 1,134 | 1,115 (98.3) | 19 (1.7) | 0.73 (0.41–1.27) |
| 41–50, n = 758  | 740 (97.6) | 18 (2.4) | 1.05 (0.58–1.83) |
| 51–60, n = 766  | 736 (96.1) | 30 (3.9) | 1.75 (1.06–2.85) |
| ≥60, n = 274    | 270 (98.5) | 4 (1.5)  | 0.66 (0.19–1.66) |
| Sex            |                        |                     |
| F, n = 3,207 | 3,141 (97.9) | 66 (2.1) | Referent |
| M, n = 1,342 | 1,300 (96.9) | 42 (3.1) | 1.54 (1.03–2.27) |
| Unreported, n = 5 | 5 (100)   | 0                     |
| Profession     |                        |                     |
| Nurses, n = 958 | 934 (97.5) | 24 (2.5) | 1.55 (0.80–3.10) |
| Physicians, n = 860 | 846 (98.4) | 14 (1.6) | Referent |
| Clinical ancillary staff, n = 383 | 374 (97.7) | 9 (2.3) | 1.46 (0.60–3.39) |
| Nonclinical ancillary staff, n = 120 | 118 (98.3) | 2 (1.7) | 1.09 (0.16–4.02) |
| Scientists/laboratory workers, n = 635 | 627 (98.7) | 8 (1.3) | 0.78 (0.31–1.84) |
| Administrative staff, n = 557 | 536 (96.2) | 21 (3.8) | 2.36 (1.19–4.80) |
| Other, n = 424 | 412 (97.2) | 12 (2.8) | 1.76 (0.79–3.88) |
| Students, n = 603 | 586 (97.2) | 17 (2.8) | 1.75 (0.85–3.65) |

*SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
filtering masks with either filtering face piece or N95 standard or eye protection or face shields) was associated with higher seroprevalence (OR 4.77, 95% CI 3.09–7.22) (Table 2; Appendix Figure 5). For staff reporting to perform AGPs we observed an even lower (1.04 (1.01–6.61)) (1/24) (Table 2; Figure 2, panel A; Appendix Figure 5).

**Symptoms and SARS-CoV-2 IgG Titers for Hospital Staff**

In our cohort, 1,272 (27.9%) persons reported current or recent (within 8 weeks before testing) presence of ≥1 symptom indicative of COVID-19 (Table 2; Appendix Figure 5), 79 (6.2%) of whom were seropositive for SARS-CoV-2 IgG (Table 2; Appendix Figure 5). Loss of smell (36 [25.0%] seropositive of 144 persons who had reported loss of smell) and loss of taste (39 [31.5%] of 124 persons) had the highest positive predictive value (Table 2; Appendix Figure 5), and seropositivity was associated with a higher number of symptoms reported (Table 3; Appendix Figure 5).

For seropositive persons, we found no major differences in SARS-CoV-2 IgG titers for different age groups, sex, comorbidities, or exposure profiles (Appendix Figure 6). However, SARS-CoV-2
IgG levels were higher for staff who reported more COVID-19-related symptoms (Appendix Figure 7). We observed the highest titers for those persons who reported diarrhea, fever, increased temperature, shivering, limb pain, and headache (Appendix Figure 7).

Value of Symptom-Based RT-PCR Testing

We initiated symptom-based RT-PCR testing of material obtained from nasopharyngeal swab specimens early during the pandemic through a dedicated COVID-19 telephone hotline. The first hospital employee with SARS-CoV-2 infection was identified on March 9, 2020, and 28 persons who had SARS-CoV-2 infections detected by RT-PCR before participating in this study were positive for SARS-CoV-2 IgG (Figure 1; Appendix Figure 8). Ten seropositive persons had a positive PCR result; 1 positive antibody testing result was obtained at another facility. However, 68 (63%) of 108 SARS-CoV-2 infections had not been diagnosed previously; data on previous testing was missing for 1 person. Among these 68 seropositive persons, 28 did not report any COVID-19-typical symptoms in the initial survey (25.9% of all seropositive staff), indicating that symptom-based testing can miss SARS-CoV-2 infection.

Table 3. Seroprevalence of SARS-CoV-2 IgG in patients and staff, by symptom onset and frequency, at a university hospital, Munich, Germany*

| Characteristic          | SARS-CoV-2IgG, no. (%) | Odds ratio (95% CI) |
|-------------------------|-----------------------|---------------------|
| **Symptom onset**       |                       |                     |
| Not applicable, n = 3,373| 3,336 (98.9)          | 37 (1.1)            |
| Past 14 days, n = 219    | 209 (95.4)            | 10 (4.6)            |
| Past 3–8 weeks, n = 943  | 883 (93.6)            | 60 (6.4)            |
| Unknown, n = 19         | 18                    | 1                   |
| **Symptom frequency, p<0.001** |                   |                     |
| 0, n = 3,273            | 3,245 (99.1)          | 28 (0.9)            |
| 1–4, n = 548            | 529 (96.5)            | 19 (3.5)            |
| 5–8, n = 491            | 454 (92.5)            | 37 (7.5)            |
| 9–14, n = 223           | 200 (89.7)            | 23 (10.3)           |
| Unknown, n = 19         | 18                    | 1                   |

*SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Analysis of Spatiotemporal Trajectories
To identify and localize potential hotspots of infection, we systematically analyzed contact between staff and COVID-19 patients by using the cumulative data for serologic analysis for staff and the patient registry. Thus, we plotted available spatial and temporal information on the presence of COVID-19 patients and SARS-CoV-2 IgG-positive staff with daily resolution on a hospital map. Visualization of these spatiotemporal mobility trajectories showed only a slight overlap between the distinct spatial and temporal hotspots of COVID-19 patients and SARS-CoV-2 IgG-positive staff (Figure 3; Videos 1-3, https://wwwnc.cdc.gov/EID/article/28/3/20-4436-V1.htm, https://wwwnc.cdc.gov/EID/article/28/3/20-4436-V2.htm, https://wwwnc.cdc.gov/EID/article/28/3/20-4436-V3.htm).

Discussion
Despite the high overall number of patients in our hospital who had COVID-19 disease, the seroprevalence of 2.4% for SARS-CoV-2 IgG among university hospital staff after the first wave in Germany is lower than that reported in previous studies (11,12). This difference might be attributed to differences in cohort composition, fast implementation of protective measures, or frequency of exposure.

Hospital staff have an increased occupational risk for contact with SARS-CoV-2-infected patients, and a high level of SARS-CoV-2 infection among HCWs involved in the care of COVID-19 patients has been reported (7,13). Consistent with these findings, the seropositivity in a population-based prospective cohort study performed in Munich in parallel with our study was 1.8% and thus lower than for this HCW cohort study (14). We did not observe higher seroprevalences in staff who reported direct patient contact, including those working in COVID-19-designated units. We also observed lower seroprevalence in staff who reported performing AGPs, possibly reflecting increased awareness and use of particularly rigorous infection prevention practices at work and in private life in this subgroup. Furthermore, the type of PPE used was not associated with seroprevalence, but 98% of staff reported routinely using surgical masks, which was required by internal hospital policy for staff involved in patient care starting on March 16, 2020, and for all staff starting...
on March 27. The almost parallel increase in SARS-CoV-2 infection cases in staff and patients is suggestive of extrinsic infection causes in both groups, such as simultaneous return from high-risk holiday areas. Consistently, exposure to SARS-CoV-2-infected private contacts or co-workers was the most critical risk factor for SARS-CoV-2 infection in our cohort. This finding underscores the need for adherence to protective measures during private, professional staff, and professional patient contacts.

Male staff in our study cohort showed a higher seroprevalence. A recent study reporting lower perceived infection risk for men than for women found that adherence to hygiene guidelines and social distancing measures might have been lower in male staff (15,16). Smokers showed a lower seroprevalence, which is in contrast to that reported in previous studies (2,6,15,17). Because smokers are more susceptible to respiratory tract infections and smoking involves hand-to-mouth contact and frequent social interactions, the lower seroprevalence is unexpected but consistent with those of other reports (18–21). Staff who had diabetes mellitus had a higher seroprevalence than staff who did not have this disease. Previously, diabetes mellitus reportedly correlated with severity of COVID-19 and associated deaths, but no increase in susceptibility to SARS-CoV-2 infection has been reported to date (22).

Serologic assessment confirmed infection in most persons who reported positive test results for SARS-CoV-2 by PCR. However, repeated testing over >4 weeks with ≥2 separate assays each did not detect antibodies in 6 persons (2 who had positive in-house and 4 who had reported positive external RT-PCR test results) (Appendix Figure 8). This finding might be explained by false-positive PCR results or by the failure to develop antibody responses after low-symptom infection, which might occur in ≤10% of convalescent-phase patients after SARS-CoV-2 infection (25).

The IgG immunoassay used for screening had a specificity of 99.89% in our study; it uses 2 SARS-CoV-2 antigens (nucleocapsid and spike 1) for detection and has an estimated sensitivity of 96.30% (Appendix Table 5). We retested all IgM-positive or IgG-positive serum samples and all serum samples that had titers of 5–10 AU/mL, which is below the cutoff, by a second assay with particularly high specificity (99.90%) that uses recombinant nucleocapsid protein as antigen. If required, additional assays were performed: either an ELISA using recombinant spike 1 protein as capture antigen, or immunoblotting that tested for antibodies against 3 different SARS-CoV-2 antigens. Serum was only considered positive if ≥2 antibody assay results were positive (Appendix). However, the requirement of such extensive confirmatory testing strengthens the notion that each test for SARS-CoV-2 antibodies requires critical evaluation.

Our study also showed that approximately two thirds of the seropositive staff had a previously undetected infection. These infections might have been oligosymptomatic or asymptomatic without even alarming medically trained personnel. Furthermore, 25 SARS-CoV-2 IgG–positive persons had not been PCR tested, despite reporting ≥1 COVID-19–compatible symptom. A total of 1,183 staff members tested seronegative despite reporting ≥1 symptom related to COVID-19. The focus on symptoms with the strongest association with seropositivity, such as loss of smell, loss of taste, fatigue, fever, and cough, might therefore be helpful in developing more accurate and economical screening algorithms. Our results highlight that symptom-based testing might miss infections in hospital staff. All 28 asymptomatic seropositive persons remained undiagnosed before the study, emphasizing the need for rigorous implementation of systematic infection prevention practices in pandemic situations. Transmission by asymptomatic and presymptomatic staff might occur at any time and will not be prevented by random testing. These results strongly support the continuous use of at least surgical masks as a simple and efficient measure for employee and patient protection.

To identify infection hotspots and putative patient/staff overlaps, we visualized the temporospatial mobility trajectories of patients and staff to monitor the infection dynamics. Real-time use of such trajectory mapping at high resolution might yield additional information that enables the reaction to proceed more quickly and intuitively to infection foci. Continuous evaluation of mobility trajectory mappings might highlight areas of recurrent infections and thus identify previously unattended needs that should be addressed for future waves of the pandemic.

Our study’s first limitation is that because this was a voluntary assessment, participation was incomplete and might have biased the results. We cannot exclude the possibility that staff members with a higher perceived risk for infection were more likely to participate. Second, symptoms and exposures were retrospectively assessed and self-reported and thus subject to a recall bias in participants knowing of their SARS-CoV-2 infection. Third, we did not assess individual adherence of mask wearing in our questionnaire, especially regarding specific, potentially
hazardous situations (e.g., during breaks, in locker rooms). Consequently, this approach does not enable us to pinpoint risk for work-related infection to specific situations.

In addition, because it was not obligatory to indicate in our questionnaire the periods during which masks were worn, the analysis reflects the protective effect of masks over the entire period. Furthermore, although we attempted a cross-sectional analysis, our data document average seroprevalence during the entire testing period. Thus, seroconversions occurring during this period might have been missed. Finally, RT-PCR testing results were available only for persons who consented to their use (4,373/4,554), limiting the possibility of cross-validating PCR-testing results with seroprevalence.

Our findings have several major implications. The infection rate for HCWs was not markedly increased, and infections occurred in parallel to the general population. We did not observe a relevant increase in SARS-CoV-2 IgG seropositivity in HCWs (including those working with COVID-19 patients) compared with staff who were not directly involved in patient care, as long as PPE was used, suggesting that PPE and other infection control practices successfully prevented transmission from SARS-CoV-2–infected patients. Interaction with SARS-CoV-2–infected co-workers or private contacts was a major risk factor for infection. The infection rate among HCWs seemed to decrease when wearing surgical face masks became obligatory in all areas of the hospital. Thus, obligatory wearing of certified surgical masks by all employees, no matter when in contact with patients, relatives, or colleagues, and, whenever tolerated, also by patients, might minimize virus transmission risks. However, it was not possible to formally separate that effect from that of minimizing personal contacts imposed by the general lock-down and a concomitant decrease in COVID-19 incidence.

In summary, the value of SARS-CoV-2 antibodies for protective immunity and their sustainability in infected persons remains unclear. Longitudinal studies with combined testing for virus-specific antibodies and their infection-neutralizing ability, as well as virus-specific T-cell immunity, are needed to estimate the longevity and protective value of SARS-CoV-2 IgG responses in hospital staff. However, our results show that patient-facing healthcare work during the SARS-CoV-2 pandemic might be safe as long as adequate PPE is used and infection prevention practices are followed, both inside and outside the hospital.

Members of the SeCoMRI Study Group: Balqees Al Darweesh, Clara Balzer, Felix Bauerdorf, Alexander Böhner, Dirk Busch, Lisena Cala, Ana Cirac, Adam Chaker, Anaïs Marie Theresa Doll, Johanna Erber, Manon Feuchttinger, Ana Galhoz, Friedemann Gebhardt, Marisa Geisberger, Markus Gerhard, Oliver Goldhardt, Katharina Gresset-Kaliebe, Natalia Graf, Florian Groß, Roman Günther, Martin Halle, Bernhard Haller, Joachim Hellemann, Andreas Henkel, Maximilian Hinz, Dieter Hoffmann, Klaus-Peter Janssen, Robert Kaczmarczyk, Verena Kappler, Percy Knolle, Florian Kohlmayer, Susanne Kossatz, Klaus Kuhn, Zsuzsanna Kurgyis, Vincent Lallinger, Judith Lammer, Paul Lingor, Elke Lorenz, Felix Mayr, Michael M. Menden, Hrvoje Mijočević, Caroline Sandra Moesta, Ruth Neuhauser, Andrea Pagani, Anna Caroline Pilz, Clarissa Prazeres da Costa, Sarah Preis, Ulrike Protzer, Michael Quante, Hedwig Roggendorf, Jürgen Ruland, Cora Scheerer, Roland M. Schmidt, Paul Schmidl, Christine Schönmann, Florian Schraml, Christoph D. Spinner, Annette Susanne Steimle-Grauer, Christian Stöß, Pavel Stupakov, Markus Thaler, Dolores Thum, Dirk Tomsitz, Wolfgang Weber, Angelika Werner, and Christof Winter.

Acknowledgments
We thank the study participants for consenting to have their data published; clinical and administrative staff at our hospital for providing contributions involved in enrollment and obtaining informed consent of study participants; technical staff of the Institute of Virology and the Institute of Clinical Chemistry for performing diagnostic tests; Yhlo (Shenzhen, China) and Mikrogen (Neuried, Germany), for providing some of the test kits for free; and the hospital board of directors for providing financial and organizational support.

About the Author
Dr. Erber is a clinician scientist in the Medical Department II of the University Hospital Munich rechts der Isar (Technical University Munich), Munich, Germany. Her primary research interests are infection control measures, and epidemiology and diagnostics of COVID-19 and other infectious diseases.

References
1. Moscola J, Sembajwe G, Jarrett M, Farber B, Chang T, McGinn T, et al.; Northwell Health COVID-19 Research Consortium. Prevalence of SARS-CoV-2 antibodies in health care personnel in the New York City Area. JAMA. 2020;324:893–5. https://doi.org/10.1001/jama.2020.14765
2. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al.; ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a
nationwide, population-based seroepidemiological study. Lancet. 2020;396:535-44. https://doi.org/10.1016/S0140-6736(20)31483-5
3. Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med. 2020;26:1193-5. https://doi.org/10.1038/s41591-020-0949-6
4. Iversen K, Bundgaard H, Hasselbalch RB, Kristensen JH, Nielsen PB, Pries-Heje M, et al. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study. Lancet Infect Dis. 2020;20:1401-8. https://doi.org/10.1016/S1473-3099(20)30589-2
5. Steensels D, Oris E, Coninx L, Nuyens D, Delforge ML, Vermeersch P, et al. Hospital-wide SARS-CoV-2 antibody screening in 3,056 staff in a tertiary center in Belgium. JAMA. 2020;324:195-7. https://doi.org/10.1001/jama.2020.11160
6. Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jiménez A, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11:3500. https://doi.org/10.1038/s41467-020-17318-x
7. Poulikakos D, Sinha S, Kalra PA. SARS-CoV-2 antibody screening in healthcare workers in a tertiary centre in North West England. J Clin Virol. 2020;129:104545. https://doi.org/10.1016/j.jcv.2020.104545
8. Medical University of Innsbruck. Ischgl study: 42.4 percent are antibody-positive [in German] [cited 2020 Aug 10]. https://www.i-med.ac.at/mypoint/news/746359.html
9. Prasser F, Kohlbacher O, Mansmann U, Bauer B, Kuhn KA. Medical University of Innsbruck. Ischgl study: 42.4 percent are antibody-positive [in German] [cited 2020 Aug 10]. https://doi.org/10.1016/j.jcv.2020.104545
10. Burian E, Jungmann F, Kaissis GA, Lohöfer FK, Spinner CD, Almirall J, Serra-Prat M, Bolíbar I, Balasso V. Risk factors for hospital admission in the 28 days following a community-acquired pneumonia diagnosis in older adults, and their contribution to increasing hospitalisation rates over time: a cohort study. BMJ Open. 2015;5:e008727. https://doi.org/10.1136/bmjopen-2015-008727
11. World Health Organization. Coronavirus disease (COVID-19) outbreak situation [cited 2020 Aug 10]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
12. Almirall J, Serra-Prat M, Bolíbar I, Balasso V. Risk factors for community-acquired pneumonia in adults: a systematic review of observational studies. Respiraion. 2017;94:299-311. https://doi.org/10.1159/000479089
13. Wei XS, Wang XR, Zhang JC, Yang WB, Ma WL, Yang BH, et al. A cluster of health care workers with COVID-19 pneumonia caused by SARS-CoV-2. J Microbiol Immunol Infect. 2020.
14. Chou R, Dana T, Buckley DI, Selph S, Fu R, Totten AM. Epidemiology of and risk factors for coronavirus infection in health care workers. Ann Intern Med. 2020;173:120-36. https://doi.org/10.7326/M20-1632
15. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Bayssón H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396:315-9. https://doi.org/10.1016/S0140-6736(20)31304-0
16. Behrens GM, Cossmann A, Stankov MV, Witte T, Ernst D, Happle C, et al. Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals. Infection. 2020;48:631-4. https://doi.org/10.1007/s15010-020-01461-0
17. Xu X, Sun J, Nie S, Li H, Kong Y, Liang M, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China. Nat Med. 2020;26:1193-5. https://doi.org/10.1038/s41591-020-0949-6
18. Grundy EJ, Suddek T, Filippidis FT, Majeed A, Corninini-Cronberg S, Smoking, SARS-CoV-2 and COVID-19: a review of reviews considering implications for public health policy and practice. Tob Induc Dis. 2020;18:58. https://doi.org/10.18332/tid/124788
19. Millett ER, De Stavola BL, Quint JK, Smeeth L, Thomas SL. Risk factors for hospital admission in the 28 days following a community-acquired pneumonia diagnosis in older adults, and their contribution to increasing hospitalisation rates over time: a cohort study. BMJ Open. 2015;5:e008727. https://doi.org/10.1136/bmjopen-2015-008727
20. Mazucanti CH, Egan JM. SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done? Immun Ageing. 2020;17:21. https://doi.org/10.1186/s12979-020-00192-y
21. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26:1200-4. https://doi.org/10.1038/s41591-020-0965-6
Address for correspondence: Paul Lingor, Department of Neurology, University Hospital rechts der Isar, Technical University of Munich, Germany, Ismaningerstrasse 22, 81675 Munich, Germany; paul.lingor@tum.de
Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany

Appendix

Questionnaire

The original survey was in German and was acquired by using a standardized, electronic questionnaire.

Baseline characteristics

Date of assessment

Baseline characteristic: Age, sex

Department:

Worksite:

Occupation

Physician Nurse

Lab Worker Hygiene Staff Clinical Ancillary Staff Cleaning Staff

Patient Transport

Administration Technical Staff IT Scientist Student Others

Do you have a patient facing role? Yes No

Exposure and personal protective equipment

In which area(s) have you been placed? (multiple answers possible)
| Work area | Currently | Past 48 hours | Past 3 to 14 days | Past 3 to 8 weeks |
|-----------|-----------|---------------|-------------------|-------------------|
| COVID-19 assigned area | | | | |
| Emergency department | | | | |
| Ward | | | | |
| Intensive care unit | | | | |
| Other | | | | |
| Aerosol generating procedures* | | | | |

*Endoscopy, bronchoscopy, tracheal intubation, non-invasive ventilation, transesophageal echo, etc.

Have you been in contact with SARS-CoV-2-positive individuals?  □ Yes  □ No

| COVID-19 contact | Currently | Past 48 hours | Past 3 to 14 days | Past 3 to 8 weeks |
|------------------|-----------|---------------|-------------------|-------------------|
| Patients at MRI  | | | | |
| Co-worker at MRI | | | | |
| Private contact  | | | | |
| Protected (mask and physical distance, or FFP2/N95 and eye protection when performing aerosol-generating procedures) | | | | |
| Unprotected (none of the abovementioned, or mask only when performing aerosol generating procedures) | | | | |

Do you use personal protective equipment?  □ Yes  □ No

If so, which ones? (multiple answers possible)
| Personal protective equipment | Currently | Past 48 hours | Past 3 to 14 days | Past 3 to 8 weeks |
|-------------------------------|-----------|---------------|-------------------|-------------------|
| Mask                          |           |               |                   |                   |
| FFP2/N95                      |           |               |                   |                   |
| FFP3                          |           |               |                   |                   |
| Protective clothing           |           |               |                   |                   |
| Eye protection or face shield |           |               |                   |                   |
| Others                        |           |               |                   |                   |

**Individual factors**

What applies to you (multiple answers possible)?

- □ Smoking
- □ Pulmonary disease
- □ Cardiovascular disease
- □ Diabetes mellitus
- □ Immunodeficiency
- □ Immunosuppressive therapy
- □ Other

Have you had COVID-19 compatible symptoms? □ Yes □ No (multiple answers possible)

| Symptoms             | Currently | Past 48 hours | Past 3 to 14 days | Past 3 to 8 weeks |
|----------------------|-----------|---------------|-------------------|-------------------|
| Exhaustion           |           |               |                   |                   |
| Fatigue              |           |               |                   |                   |
| Cough                |           |               |                   |                   |
| Shortness of breath  |           |               |                   |                   |
| Rhinitis             |           |               |                   |                   |
| Loss of smell        |           |               |                   |                   |
| Loss of taste        |           |               |                   |                   |
| Sore throat          |           |               |                   |                   |
| Headache             |           |               |                   |                   |
| Limb pain            |           |               |                   |                   |
Shivering
Diarrhea
Elevated temperature (37.3–37.9°C)
Fever (>38°C)

Current body temperature □□ °C

Have you ever been tested for SARS-CoV-2? □ Yes □ No

if so: □ Past 14 days □ More than 14 days ago

Where? □ MRI □ Registered physician □ Department Of Public Order

How? □ Nasopharyngeal swab □ Blood □ Stool

Test result:
□ Pending □ Positive for SARS-COV-2 □ Negative for SARS-CoV-2

COVID-19 disease

Have you already had COVID-19? □ Yes □ No

Treatment: □ Outpatient/at home □ Inpatient/normal ward □ Ward and intensive care unit

**Calculation of Specificity and Sensitivity of the SARS-CoV-2 Antibody Tests**

IgG and IgM were determined in 4,554 and 1,708 serum samples, respectively, by using a paramagnetic particle chemiluminescent immunoassay (CLIA) on an iFlash 1800 immunoassay analyzer (Shenzhen Yhlo Biotech Co., Shenzhen, China). This assay was selected as a screening assay because it detects antibodies directed against either SARS-CoV-2 S1 or N protein. According to the manufacturer’s instructions, values ≥10 AU/mL were considered positive. SARS-CoV-2 IgG titers were positive (≥10 AU/L) in 108 persons, negative (<5 AU/L) in 4,411 persons, and 35 persons had borderline results (5–10 AU/mL) (Appendix Figure 5).

To determine the sensitivity and specificity of the screening assay, confirmatory testing was performed in all serum samples that tested positive for IgM or IgG, all serum samples with
IgG values between 5 and 10 AU/mL, and all serum samples from SARS-CoV-2 PCR-positive persons. For confirmation, the total antibodies against SARS-CoV-2 N protein were determined by using an electrochemiluminescent immunoassay (ECLIA) on a Cobas e411 analyzer (Roche Diagnostics, Mannheim, Germany). In all samples with incongruent results, IgG against SARS-CoV-2 S1 protein were determined by using an ELISA (Euroimmun, Luebeck, Germany), while immunoblot was used to differentiate antibodies against N, S1, and the receptor binding domain (RBD) of SARS-CoV-2 from those against seasonal coronaviruses (Mikrogen, Neuried, Germany).

Tests were considered correct if the presence of antibodies was confirmed by at least one more independent assay. Of the 108 serum samples that tested positive in the Yhlo screening assay, 93 also tested positive in the Roche IgG assay, eight were confirmed by immunoblotting (Appendix Tables 1 and 4). In one individual the screening result was considered specific due to high IgG titer and concomitant IgM positivity although no confirmatory testing could be performed (Appendix Tables 1 and 4, Sample-ID 18). In another individual testing only IgG positive, the serum amount was insufficient for confirmatory testing (Appendix Table 3, Sample-ID 114). Five IgG test results were considered false positive because screening IgG results were not confirmed by any of the other assays (Appendix Table 3). This resulted in a specificity of 99.89% for the IgG assay (4,441/4,446; Appendix Table 5).

IgM was screened in all patients until May 4 (n = 1,620). Six patients lacking prevalence of SARS-CoV-2 IgG tested positive for IgM (6/1,620). Because this could not be confirmed by the Roche ECLIA detecting IgM and IgG, these samples were considered false positive (S4 Table). If the Roche assay would have a 100% sensitivity, this would result in a specificity of 99.63% for the IgM assay. Due to the lack of a third assay, this, however, has to be considered preliminary.

To determine the sensitivity of the Yhlo IgG screening assay, 35 samples with detectable values between 5 and 10 AU/mL, i.e., below the recommended cutoff of the assay, were retested with both the Roche and the Euroimmun assay. Four samples tested positive in the Roche and Euroimmun assays, and were therefore considered false negative in the Yhlo screening assay (Appendix Tables 1 and 4). This enabled us to estimate the overall sensitivity of the IgG assay at 96.30% (104/108; Appendix Table 5).
For estimation of seroprevalence, persons who had ≥2 positive antibody test results (n = 106) as well as 2 persons with positive SARS-CoV-2 PCR tests that seroconverted during follow-up, were considered seropositive (108/4,554) resulting in a seroprevalence of 2%–4%. The IgG levels of seropositive persons were inversely correlated with the time of testing (rho = −0.22, [95% CI −0.39 to −0.03]) (Appendix Figure 5).

From May 5, persons were tested for SARS-CoV-2 IgM if specific SARS-CoV-2 IgG was detected or typical symptoms of COVID-19 were reported (n = 88). Overall, concomitant SARS-CoV-2 IgG and IgM was found in 22 patients (22/1,708), of these nine before May 5 (Appendix Figure 2).

| Sample ID | SARS-CoV-2 PCR | YHLO IgG (AU/mL) | YHLO IgM (AU/mL) | Roche IgG IgM (COI) | Euroimmun IgG | Mikrogen recomLine |
|-----------|----------------|------------------|------------------|---------------------|---------------|-------------------|
| 1         | ** POSITIVE    | (60.12)          | POSITIVE (19.27) | POSITIVE (14.42)    | **            | **                |
| 2         | ** POSITIVE    | (92.39)          | POSITIVE (17.93) | POSITIVE (52.30)    | **            | **                |
| 3         | ** POSITIVE    | (64.82)          | POSITIVE (31.04) | POSITIVE (25.83)    | **            | **                |
| 4         | § POSITIVE     | (113.83)         | NEGATIVE (1.78)  | POSITIVE (66.12)    | **            | **                |
| 5         | §‡ POSITIVE    | (93.54)          | NEGATIVE (2.43)  | POSITIVE (21.33)    | **            | **                |
| 6         | ** POSITIVE    | (109.62)         | NEGATIVE (3.46)  | POSITIVE (49.23)    | **            | **                |
| 7         | ** POSITIVE    | (102.26)         | NEGATIVE (2.36)  | POSITIVE (17.38)    | **            | **                |
| 8         | ** POSITIVE    | (33.60)          | NEGATIVE (2.80)  | POSITIVE (9.08)     | **            | **                |
| 9         | ** POSITIVE    | (28.28)          | NEGATIVE (2.80)  | NEGATIVE (0.06)     | NEGATIVE      | POSITIVE          |
| 10        | ** POSITIVE    | (38.15)          | NEGATIVE (4.40)  | POSITIVE (13.05)    | **            | **                |
| 11        | ** POSITIVE    | (113.58)         | NEGATIVE (3.05)  | POSITIVE (65.42)    | **            | **                |
| 12        | § POSITIVE     | (96.21)          | NEGATIVE (1.91)  | POSITIVE (47.08)    | **            | **                |
| 13        | § POSITIVE     | (78.86)          | NEGATIVE (2.29)  | POSITIVE (32.81)    | **            | **                |
| 14        | ‡ POSITIVE     | (107.45)         | NEGATIVE (0.59)  | POSITIVE (14.49)    | **            | **                |
| 15        | ‡ POSITIVE     | (41.99)          | NEGATIVE (2.59)  | POSITIVE (2.98)     | **            | **                |
| 16        | ‡ POSITIVE     | (69.45)          | NEGATIVE (0.80)  | NEGATIVE (0.055)    | NEGATIVE      | POSITIVE          |
| 17        | ** POSITIVE    | (84.41)          | NEGATIVE (5.76)  | POSITIVE (40.43)    | **            | **                |
| 18        | ** POSITIVE    | (78.97)          | POSITIVE (34.76) | **                   | **            | **                |
| 19        | §‡ POSITIVE    | (12.45)          | NEGATIVE (0.83)  | NEGATIVE (0.45)     | BORDERSLINE   | POSITIVE          |
| 20        | ** POSITIVE    | (86.18)          | NEGATIVE (1.14)  | POSITIVE (19.89)    | **            | **                |
| 21        | ** POSITIVE    | (22.12)          | NEGATIVE (0.73)  | POSITIVE (1.81)     | **            | **                |
| 22        | ** POSITIVE    | (92.35)          | NEGATIVE (19.96) | POSITIVE (28.59)    | **            | **                |
| 23        | ** POSITIVE    | (100.84)         | NEGATIVE (11.19) | POSITIVE (84.33)    | **            | **                |
| 24        | ** POSITIVE    | (30.66)          | NEGATIVE (0.48)  | NEGATIVE (0.054)    | NEGATIVE      | POSITIVE          |
| 25        | ‡ POSITIVE     | (95.56)          | NEGATIVE (6.06)  | POSITIVE (27.94)    | **            | **                |
| 26        | ** POSITIVE    | (91.06)          | NEGATIVE (1.41)  | POSITIVE (48.79)    | **            | **                |
| 27        | ** POSITIVE    | (25.61)          | NEGATIVE (1.89)  | POSITIVE (4.55)     | **            | **                |
| 28        | § POSITIVE     | (35.34)          | NEGATIVE (1.67)  | POSITIVE (7.32)     | **            | **                |
| 29        | ** POSITIVE    | (72.10)          | POSITIVE (22.39) | POSITIVE (75.58)    | **            | **                |
| 30        | § POSITIVE     | (97.45)          | NEGATIVE (4.91)  | POSITIVE (65.48)    | **            | **                |
| 31        | § POSITIVE     | (59.51)          | NEGATIVE (10.26) | POSITIVE (79.13)    | **            | **                |
| 32        | ** POSITIVE    | (42.14)          | POSITIVE (17.68) | POSITIVE (14.92)    | **            | **                |
| 33        | § POSITIVE     | (49.91)          | NEGATIVE (1.19)  | POSITIVE (27.04)    | **            | **                |
| 34        | §‡ POSITIVE    | (97.02)          | NEGATIVE (10.00) | POSITIVE (99.14)    | **            | **                |
| 35        | §‡ POSITIVE    | (91.68)          | NEGATIVE (1.89)  | POSITIVE (14.13)    | **            | **                |
| 36        | ** POSITIVE    | (35.20)          | NEGATIVE (1.98)  | POSITIVE (2.63)     | **            | **                |
| 37        | § POSITIVE     | (55.92)          | NEGATIVE (0.53)  | POSITIVE (10.45)    | **            | **                |
| 38        | ** POSITIVE    | (27.81)          | NEGATIVE (0.48)  | POSITIVE (14.44)    | **            | **                |
| 39        | ** POSITIVE    | (98.57)          | NEGATIVE (4.07)  | POSITIVE (70.04)    | **            | **                |
| 40        | ** POSITIVE    | (86.47)          | NEGATIVE (9.97)  | POSITIVE (89.22)    | **            | **                |
| 41        | ** POSITIVE    | (12.51)          | NEGATIVE (1.06)  | POSITIVE (2.87)     | **            | **                |

Page - 6 - of 16
| Sample ID | SARS-CoV-2 PCR | YHLO IgG (AU/mL) | YHLO IgM (AU/mL) | Roche IgG IgM (COI) | Euroimmun IgG | Mikrogen recomLine |
|-----------|----------------|------------------|------------------|---------------------|---------------|-------------------|
| 45        | §‡ POSITIVE    | (91.08) NEGATIVE | (0.43) POSITIVE  | (89.17)             | □ □           | □ □               |
| 46        | ** POSITIVE    | (45.18) NEGATIVE | (1.76) POSITIVE  | (30.29)             | □ □           | □ □               |
| 47        | §‡ POSITIVE    | (113.23) NEGATIVE| (2.61) POSITIVE  | (40.58)             | □ □           | □ □               |
| 48        | ** POSITIVE    | (73.79) NEGATIVE | (0.67) POSITIVE  | (43.39)             | □ □           | □ □               |
| 49        | ** POSITIVE    | (93.50) POSITIVE | (10.14) POSITIVE | (27.46)             | □ □           | □ □               |
| 50        | §‡ POSITIVE    | (84.28) NEGATIVE | (0.68) POSITIVE  | (50.96)             | □ □           | □ □               |
| 51        | §‡ POSITIVE    | (96.75) NEGATIVE | (4.80) POSITIVE  | (10.30)             | □ □           | □ □               |
| 52        | ** POSITIVE    | (36.27) NEGATIVE | (0.85) POSITIVE  | (2.72)              | □ □           | □ □               |
| 53        | ** POSITIVE    | (10.52) NEGATIVE | (0.37) NEGATIVE  | (0.061)             | NEGATIVE      | POSITIVE          |
| 54        | § POSITIVE     | (49.49) NEGATIVE | (0.94) POSITIVE  | (39.16)             | □ □           | □ □               |
| 55        | ** POSITIVE    | (50.98) NEGATIVE | (1.54) POSITIVE  | (78.15)             | □ □           | □ □               |
| 56        | §‡ POSITIVE    | (83.97) NEGATIVE | (5.40) POSITIVE  | (45.04)             | □ □           | □ □               |
| 57        | ‡ POSITIVE     | (32.83) NEGATIVE | (0.24) POSITIVE  | (19.70)             | □ □           | □ □               |
| 58        | § POSITIVE     | (72.67) NEGATIVE | (3.35) POSITIVE  | (11.77)             | □ □           | □ □               |
| 59        | ** POSITIVE    | (60.13) NEGATIVE | (2.74) NEGATIVE  | (0.055)             | NEGATIVE      | POSITIVE          |
| 60        | ** POSITIVE    | (66.95) NEGATIVE | (2.27) POSITIVE  | (39.01)             | □ □           | □ □               |
| 61        | ‡ POSITIVE     | (47.80) NEGATIVE | (1.08) POSITIVE  | (19.42)             | □ □           | □ □               |
| 62        | ** POSITIVE    | (82.89) NEGATIVE | (4.19) POSITIVE  | (60.83)             | □ □           | □ □               |
| 63        | § POSITIVE     | (23.44) NEGATIVE | (0.42) POSITIVE  | (14.57)             | □ □           | □ □               |
| 64        | ** POSITIVE    | (20.75) NEGATIVE | (1.49) POSITIVE  | (21.14)             | □ □           | □ □               |
| 65        | ** POSITIVE    | (45.24) NEGATIVE | (0.72) POSITIVE  | (53.24)             | □ □           | □ □               |
| 66        | ** POSITIVE    | (33.84) NEGATIVE | (0.29) POSITIVE  | (17.67)             | □ □           | □ □               |
| 67        | ** POSITIVE    | (14.69) NEGATIVE | (0.49) POSITIVE  | (10.88)             | □ □           | □ □               |
| 68        | ‡ POSITIVE     | (54.55) POSITIVE | (22.09) POSITIVE | (62.24)             | □ □           | □ □               |
| 69        | ‡ POSITIVE     | (46.11) NEGATIVE | (0.95) POSITIVE  | (36.16)             | □ □           | □ □               |
| 70        | ‡ POSITIVE     | (10.01) NEGATIVE | (1.34) POSITIVE  | (9.90)              | □ □           | □ □               |
| 71        | ** POSITIVE    | (52.17) NEGATIVE | (0.62) POSITIVE  | (32.00)             | □ □           | □ □               |
| 72        | ** POSITIVE    | (13.79) NEGATIVE | (0.73) POSITIVE  | (8.11)              | □ □           | □ □               |
| 73        | ** POSITIVE    | (89.38) POSITIVE | (29.98) POSITIVE | (91.78)             | □ □           | □ □               |
| 74        | ** POSITIVE    | (68.40) NEGATIVE | (4.42) POSITIVE  | (90.23)             | □ □           | □ □               |
| 75        | ** POSITIVE    | (27.70) NEGATIVE | (0.40) POSITIVE  | (6.11)              | □ □           | □ □               |
| 76        | ** POSITIVE    | (82.56) POSITIVE | (19.32) POSITIVE | (102.00)            | □ □           | □ □               |
| 77        | ** POSITIVE    | (58.50) NEGATIVE | (0.41) POSITIVE  | (84.81)             | □ □           | □ □               |
| 78        | §‡ POSITIVE    | (74.31) NEGATIVE | (0.78) POSITIVE  | (68.42)             | □ □           | □ □               |
| 79        | ** POSITIVE    | (69.18) NEGATIVE | (0.50) POSITIVE  | (81.05)             | □ □           | □ □               |
| 80        | ** POSITIVE    | (36.63) NEGATIVE | (1.11) POSITIVE  | (62.51)             | □ □           | □ □               |
| 81        | ‡ POSITIVE     | (64.48) NEGATIVE | (0.80) POSITIVE  | (56.41)             | □ □           | □ □               |
| 82        | ** POSITIVE    | (82.53) POSITIVE | (22.54) POSITIVE | (81.01)             | □ □           | □ □               |
| 83        | ** POSITIVE    | (10.52) NEGATIVE | (0.48) NEGATIVE  | (0.053)             | NEGATIVE      | POSITIVE          |

*No material for further tests available, † positive at follow-up visit, COI: Cutoff Index, § positive SARS-CoV-2 PCR extern, § positive SARS-CoV-2 PCR in-house, •• not available.
### Appendix Table 2. Summary of confirmatory assays

| Sample ID | YHLO IgG (AU/mL) | YHLO IgM (AU/mL) | Roche IgG‡ IgM (COI) | Mikrogen recomLine immunoblot | Final result | No. patients |
|-----------|------------------|------------------|----------------------|-----------------------------|--------------|--------------|
| 109       | POSITIVE         | **               | POSITIVE             | **                         | POSITIVE     | 93           |
| 110       | POSITIVE         | **               | NEGATIVE             | NEGATIVE/BOORDERLINE        | POSITIVE     | 8            |
| 111       | POSITIVE         | **               | **                   | **                         | BIOSHIFT     | 5            |
| 112       | NEGATIVE         | **               | **                   | NEGATIVE                    | NEGATIVE     | 1            |
| 113       | NEGATIVE         | **               | **                   | NEGATIVE                    | Excluded from calculation of specificity | 1            |
| 114       | **               | **               | **                   | **                         | **           | 2            |

*Initially negative, but positive at follow-up visit, † no material for further tests available, § in-house SARS-CoV-2 PCR positive, COI: Cutoff index.

### Appendix Table 3. Samples with positive IgG against SARS-CoV-2 that could not be confirmed

| Sample ID | YHLO IgG (AU/mL) | YHLO IgM (AU/mL) | Roche IgG‡ IgM (COI) | Mikrogen recomLine | Final result |
|-----------|------------------|------------------|----------------------|-------------------|--------------|
| 109       | POSITIVE         | (26.78)          | NEGATIVE             | (0.19)            | NEGATIVE     |
| 110       | POSITIVE         | (23.75)          | NEGATIVE             | (1.17)            | NEGATIVE     |
| 111       | POSITIVE         | (10.14)          | NEGATIVE             | (0.82)            | NEGATIVE     |
| 112       | POSITIVE         | (21.46)          | NEGATIVE             | (0.44)            | NEGATIVE     |
| 113       | POSITIVE         | (12.13)          | NEGATIVE             | (0.50)            | NEGATIVE     |
| 114       | POSITIVE         | (11.75)          | NEGATIVE             | (0.28)            | NEGATIVE     |

*No material for further tests available.

### Appendix Table 4. Samples with positive IgM against SARS-CoV-2 that could not be confirmed

| Sample ID | YHLO IgG (AU/mL) | YHLO IgM (AU/mL) | Roche IgG‡ IgM (COI) | Mikrogen recomLine |
|-----------|------------------|------------------|----------------------|-------------------|
| 115       | NEGATIVE         | (0.98)           | POSITIVE             | (11.51)           |
| 116       | NEGATIVE         | (0.41)           | POSITIVE             | (13.17)           |
| 117       | NEGATIVE         | (2.90)           | POSITIVE             | (13.41)           |
| 118       | NEGATIVE         | (0.28)           | POSITIVE             | (12.23)           |
| 119       | NEGATIVE         | (0.45)           | POSITIVE             | (10.27)           |
| 120       | NEGATIVE         | (0.14)           | POSITIVE             | (265.82)          |

### Appendix Table 5. Calculation of specificity and sensitivity

| Result | ≥2 Positive confirmatory tests or concomitant IgM | <2 Positive confirmatory tests | Total |
|--------|-----------------------------------------------|--------------------------------|-------|
| Screening assay positive | True positive, n = 104 | False positive, n = 5 | n = 109† |
| Screening assay negative | False negative, n = 4 | True negative, n = 4,441 | n = 4,445 |
| Total | n = 108 | n = 4,446 | 4,554 |

†Serum material was insufficient for confirmatory testing for 1 seropositive patients; 2 patients showed seroconversion at follow-up visit.
Appendix Figure 1. Study flowchart illustrating the testing algorithm and included results. CLIA, chemiluminescent immunoassay; ECLIA, electrochemiluminescent immunoassay; MRI, Munich rechts der Isar Hospital; TUM, Technical University Munich.
Appendix Figure 2. SARS-CoV-2 IgG and IgM levels, which were detected by using a paramagnetic particle chemiluminescent immunoassay (Shenzhen Yloh Biotech; Shenzhen, China). The cutoff was defined as ≥10 AU/mL per assay instruction, and is indicated by a dashed line. Boxplots show medians (thick middle line), as well as first and third quartiles (box boundaries), while the whiskers indicate ranges. IgG was measured in all participants (n = 4554) (A). The IgM levels of all participants tested up to May 4, 2020 (n = 1620) are depicted in (B). Thereafter, IgM was only tested in cases with positive IgG results (n = 88, data not shown). All positive IgG and IgM results (up to May 4), as well as borderline results (>5 AU/L and <10) are depicted in (C). (D) Shows the correlation of IgG and IgM levels of all participants tested for both immunoglobulins (n = 1620 = 1708). (E) IgG levels detected in seropositive persons are plotted per study day. Spearman’s rank correlation coefficient was used to evaluate the association between the time point of IgG testing and the IgG titer level.
Appendix Figure 3. Relative frequency of requested diagnostics, therapies, and spatial information between patients given a diagnosis of COVID-19 and non-COVID-19 pneumonia from December 1, 2019 to June 10, 2020 normalized by each patient group. Diagram demonstrating that the diagnostic and therapeutic facilities for patients with COVID-19 and non-COVID-19 pneumonia were used differentially by the two patient groups, further limiting the possibilities of infection. CC, cardiovascular clinic; CT_1 and CT_2, spatially distinct CT scanners; CW_1, COVID-19 admission ward; CW_2, COVID-19 ward; DU, dialysis unit; ED, emergency department; SC, social counselling; XR_A and XR_B, spatially distinct x-ray units.
Appendix Figure 4. Age and sex distribution of study participants. Population pyramid indicates age and sex distribution of patients.
Appendix Figure 5. Graphic representation of all odds ratios for seropositivity to SARS-CoV-2 IgG represented in S1–S3 Tables. Odds ratios with exact 95% confidence intervals (mid-p intervals) are presented. FFP, filtering face piece; FFP 2, use of masks with 94% or ≥95% filter capacity for particles >0.6 µm; FFP3, use of masks with 99% filter capacity for particles >0.6 µm; Lab, laboratory, Ref, reference; PPE, personal protective equipment.
Appendix Figure 6. Distribution of SARS-CoV-2 IgG levels stratified for personal/occupational risk factors. IgG levels were compared in seropositive staff of different age (A), sex (B), and with different comorbidities or smoking status (C), reported COVID-19 contact (D), as well as occupational exposures (E) and use of distinct personal protective equipment. Boxplots show medians (thick middle line), as well as the first and third quartiles (box boundaries), while the whiskers indicate ranges. Medians and quartiles are depicted in the adjacent table. ED, emergency department; FFP, filtering face piece; ICU, intensive care unit.
Appendix Figure 7. SARS-CoV-2 IgG levels and symptoms. Distribution of antibodies stratified for symptom frequency (A) and character (B). Boxplots show medians (thick middle line), as well as first and third quartiles (box boundaries). Values are annotated in the adjacent table. Whiskers indicate ranges. Q, quartile.
Appendix Figure 8. Time course of SARS-CoV-2 antibody and PCR test results in 33 employees. PCR test results were available for 33 employees (numbered consecutively) who had tested positive for SARS-CoV-2 by PCR at least once. Plots show all SARS-CoV-2 IgG and IgM results, as well as PCR tests performed before June 15, 2020, for these patients. Five patients (Nos. 7, 14, 16, 19, and 29) tested negative for IgG at the time of the serosurvey. Seroconversion could be detected for patient no. 19 at follow-up assessment. Pos, positive; Neg, negative.